Study Shows Proven Cost-Effective Supply of Generic Medications Through Nonprofit Models
A new study demonstrates that nonprofit healthcare models like CivicaScript can reliably provide essential generic medicines at major savings for patients and insurers, highlighting a path toward more affordable drug access.
A recent study highlights the potential of nonprofit healthcare models to reliably supply essential generic medications at significantly reduced costs. Conducted by researchers from Cambridge Judge Business School affiliated with Intermountain Health, the study focused on the case of CivicaScript, a nonprofit drug manufacturer operating in the United States. The study's findings reveal that CivicaScript can provide generic drugs, such as abiraterone acetate — a treatment for metastatic prostate cancer — at prices that save patients over 60%, while insurers see savings exceeding 90%. This demonstrates that prioritizing patient access over profit in the pharmaceutical industry can be both feasible and highly effective.
Published in NEJM Catalyst, the research assessed pharmacy claims data from September to December 2023, comparing costs for CivicaScript members with those of other suppliers. The results showed a 64% reduction in costs for patients and a 92% reduction for insurers. The success of CivicaScript’s model indicates that reframing business strategies around sustainability and affordability rather than profit maximization can produce substantial economic benefits.
CivicaScript's approach involves transparent, scalable operations rooted in the healthcare utility (HCU) model — a self-sustaining nonprofit organization formed by healthcare institutions. With over 100 million members across more than 20 institutional partners and multiple states, CivicaScript offers medications at wholesale prices, such as abiraterone acetate, which is still expensive despite patent expiration. Their model involves transparent pricing, including a low wholesale cost and a simple retail markup.
Despite its promising results, CivicaScript faces resistance from traditional supply chain players like pharmacy benefit managers (PBMs), which often inflate drug prices significantly. Reports from the Federal Trade Commission have documented such markups, highlighting challenges to implementing cost-saving models industry-wide.
The research underscores the potential for nonprofit and collaborative models to address systemic issues in drug pricing. As industry debates continue over patent laws and market failures, CivicaScript’s success offers a scalable example of how aligning interests around affordability can transform healthcare costs.
Source: https://medicalxpress.com/news/2025-05-generic-drugs-reliably-big.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
HDAC1 Enzyme Acts as a Tumor Suppressor in Aggressive T-Cell Lymphomas
New research reveals the tumor-suppressing role of HDAC1 enzyme in aggressive T-cell lymphomas, offering promising avenues for targeted therapies using epigenetic modulation.
Revolutionary AI Enables Cancer Diagnosis on Standard Laptops
A new lightweight AI model developed by Professor Kenji Suzuki enables accurate cancer diagnosis on standard laptops, promising to improve accessibility and efficiency in medical imaging.
Groundbreaking Achievement: First Successful Human Bladder Transplant Performed in the U.S.
Surgeons at UCLA have successfully performed the world's first human bladder transplant, providing new hope for patients with severe bladder conditions.